← Eichor
Study identifier: NCT07323368 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Advancing Reperfusion Therapy for Ischemic Stroke: Perfusion-guided Endovascular Intervention for Medium Vessel Occlusion Therapy

Condition: Stroke Ischemic · Medium Vessel Occlusions  ·  Sponsor: Beijing Tiantan Hospital

PhaseNA
Planned participants568
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of perfusion-guided endovascular treatment (EVT) compared to standard medical care for patients with acute ischemic stroke due to medium vessel occlusion (MeVO) within 24 hours from symptom onset.

This description comes directly from the study's public registry record.

Talk to the study team

Yunyun Xiong, professor  ·  86-10-59978350  ·  xiongyunyun@bjtth.org

Always discuss trial participation with your own doctor first.

Locations (6)

Beijing tiantan hospitalBeijing, Beijing Municipality, ChinaRecruiting
Beijing Daxing District People's HospitalBeijing, Beijing Municipality, ChinaRecruiting
Xingtang County People's HospitalLongzhou, Hebei, ChinaRecruiting
Luoyang Yiluo HospitalLuoyang, Henan, ChinaRecruiting
People's Hospital of QueshanPanlong, Henan, ChinaRecruiting
Changle People's HospitalChangle, Shandong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07323368